S.Korea reaches deal to buy 10 million doses of SK Bioscience's COVID vaccine -KDCA

SK Bioscience Co

21/03/2022 05:27

SEOUL, March 21 (Reuters) - South Korea has reached a deal
to buy 10 million doses of SK Bioscience's coronavirus vaccine
candidate, the Korea Disease Control and Prevention Agency
(KDCA) said on Monday. 
    The South Korean vaccine developer is conducting a Phase 3
trial with the goal of securing formal approval for public
distribution in the first half of 2023, the KDCA said. 

 (Reporting by Hyonhee Shin; Editing by Tom Hogue)
 ((hyonhee.shin@thomsonreuters.com;))